English
|
简体中文
|
繁體中文
|
한국어
|
日本語
Home
|
About us
|
Services
|
Partners
|
Events
|
Contact us
|
Login
Tuesday, December 16, 2025
Press Releases for Monday, December 15, 2025
SAKENOVA: 28-Year-Old Master Brewer Pioneers AI-Driven Sake Revolution, Achieving 40% Cost Reduction While Winning International Gold Medals
22:00 HKT/SGT
GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes
21:09 HKT/SGT
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
21:00 HKT/SGT
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
21:00 HKT/SGT
NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport
18:41 HKT/SGT
希迪智駕招股進行中:構築智能駕駛產業化底座 多場景落地打開成長空間
18:06 HKT/SGT
希迪智驾招股进行中:构筑智能驾驶产业化底座 多场景落地打开成长空间
18:06 HKT/SGT
NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz
18:04 HKT/SGT
Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares
17:59 HKT/SGT
雲頂新耀發佈2030戰略規劃 管理層及主要股東增持超3800萬港元股份
16:59 HKT/SGT
云顶新耀发布2030战略规划 管理层及主要股东增持超3800万港元股份
16:59 HKT/SGT
Indonesia's KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge
13:00 HKT/SGT
国资护航+技术壁垒+优质保荐 华芢生物(02396.HK)PDGF管线直指18A赛道确定性价值
11:05 HKT/SGT
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations
09:51 HKT/SGT
國資護航+技術壁壘+優質保薦 華芢生物(02396.HK)PDGF管線直指18A賽道確定性價值
09:28 HKT/SGT
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
07:30 HKT/SGT
ACN Search:
Abdullah Ayed Al Mazny, General Manager at Desert Dragon (ICS Arabia), and Ghufran Hamid, CEO of XDS, at the '10Mw Immersive Cooling for Ai Worlkload' Signing Ceremony on July 8, 2025.
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home
|
About us
|
Services
|
Partners
|
Events
|
Login
|
Contact us
|
Cookies Policy
|
Privacy Policy
|
Disclaimer
|
Terms of Use
|
RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575